[go: up one dir, main page]

TNSN06370A1 - Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale - Google Patents

Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale

Info

Publication number
TNSN06370A1
TNSN06370A1 TNP2006000370A TNSN06370A TNSN06370A1 TN SN06370 A1 TNSN06370 A1 TN SN06370A1 TN P2006000370 A TNP2006000370 A TN P2006000370A TN SN06370 A TNSN06370 A TN SN06370A TN SN06370 A1 TNSN06370 A1 TN SN06370A1
Authority
TN
Tunisia
Prior art keywords
dans
des
anormale
traitement
une
Prior art date
Application number
TNP2006000370A
Other languages
English (en)
Inventor
Lu
John Charles Kath
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN06370(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN06370A1 publication Critical patent/TNSN06370A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne un composé de formule (I) : Dans laquelle R1 à R4 répondent aux définitions figurant dans le présent mémoire. Ces dérivés de pyrimidine nouveaux sont utiles dans le traitement d'une croissance cellulaire anormale, telle que le cancer, chez des mammifères. La présente invention concerne également une méthode d'utilisation de ces composés dans le traitement d'une croissance cellulaire anormale chez des mammifères, notamment des êtres humains, et des compositions pharmaceutiques contenant ces composés.
TNP2006000370A 2004-05-14 2006-11-13 Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale TNSN06370A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57131204P 2004-05-14 2004-05-14
PCT/IB2005/001201 WO2005111023A1 (fr) 2004-05-14 2005-05-02 Derives de pyrimidine pour le traitement de la croissance cellulaire anormale

Publications (1)

Publication Number Publication Date
TNSN06370A1 true TNSN06370A1 (fr) 2008-02-22

Family

ID=34966230

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2006000370A TNSN06370A1 (fr) 2004-05-14 2006-11-13 Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale

Country Status (27)

Country Link
EP (1) EP1751143A1 (fr)
JP (1) JP4099212B2 (fr)
KR (1) KR100886990B1 (fr)
CN (2) CN1953974A (fr)
AP (1) AP2241A (fr)
AR (1) AR049097A1 (fr)
AU (2) AU2005243397A1 (fr)
BR (1) BRPI0511138A (fr)
CA (1) CA2566707A1 (fr)
CR (1) CR8749A (fr)
EA (1) EA200601796A1 (fr)
EC (1) ECSP066997A (fr)
GE (1) GEP20104875B (fr)
GT (1) GT200500113A (fr)
IL (1) IL178828A0 (fr)
MA (1) MA28583B1 (fr)
MX (1) MXPA06011890A (fr)
NL (2) NL1029045C2 (fr)
NO (1) NO20064576L (fr)
NZ (1) NZ550448A (fr)
PA (1) PA8632601A1 (fr)
PE (1) PE20060240A1 (fr)
TN (1) TNSN06370A1 (fr)
TW (1) TWI303635B (fr)
UY (1) UY28894A1 (fr)
WO (1) WO2005111023A1 (fr)
ZA (1) ZA200608394B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1763514A2 (fr) * 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Composes pyrimidinediamines a substitution cycloalkyle et leurs utilisations
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
AU2006327871A1 (en) * 2005-12-21 2007-06-28 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
NZ580372A (en) * 2007-04-18 2012-01-12 Pfizer Prod Inc Pyrimidine and triazine derivatives including a sulfonamide group for the treatment of abnormal cell growth such as cancer
CN101903357A (zh) * 2007-07-17 2010-12-01 里格尔药品股份有限公司 作为pkc抑制剂的环状胺取代的嘧啶二胺
CA2707653A1 (fr) * 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Nouveaux composes
PT2300013T (pt) * 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
WO2014174745A1 (fr) * 2013-04-26 2014-10-30 国立大学法人京都大学 INHIBITEUR D'Eg5
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
CN111732548B (zh) * 2020-06-11 2022-06-17 浙江大学 N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途
WO2024140671A1 (fr) * 2022-12-29 2024-07-04 南京昕瑞再生医药科技有限公司 Dérivé tricyclique fusionné, composition pharmaceutique le comprenant et son utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2003030909A1 (fr) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer
ES2338545T3 (es) * 2002-12-20 2010-05-10 Pfizer Products Inc. Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
NL1029045A1 (nl) 2005-11-15
ZA200608394B (en) 2008-05-28
PA8632601A1 (es) 2006-06-02
AP2241A (en) 2011-06-01
EA200601796A1 (ru) 2007-04-27
AU2009238255A1 (en) 2009-12-03
NL1031845A1 (nl) 2006-07-31
NL1031845C2 (nl) 2006-11-23
EP1751143A1 (fr) 2007-02-14
GEP20104875B (en) 2010-01-11
CR8749A (es) 2006-12-05
CA2566707A1 (fr) 2005-11-24
KR20070012477A (ko) 2007-01-25
KR100886990B1 (ko) 2009-03-04
NO20064576L (no) 2006-11-07
ECSP066997A (es) 2007-02-28
AU2005243397A1 (en) 2005-11-24
PE20060240A1 (es) 2006-04-01
MA28583B1 (fr) 2007-05-02
TWI303635B (en) 2008-12-01
AP2006003790A0 (en) 2006-10-31
NZ550448A (en) 2010-11-26
JP4099212B2 (ja) 2008-06-11
CN1953974A (zh) 2007-04-25
CN102127058A (zh) 2011-07-20
IL178828A0 (en) 2007-03-08
WO2005111023A1 (fr) 2005-11-24
UY28894A1 (es) 2005-12-30
BRPI0511138A (pt) 2007-11-27
NL1029045C2 (nl) 2006-06-02
JP2007537234A (ja) 2007-12-20
AR049097A1 (es) 2006-06-28
GT200500113A (es) 2006-01-10
MXPA06011890A (es) 2006-12-14
TW200539871A (en) 2005-12-16

Similar Documents

Publication Publication Date Title
MA31319B1 (fr) Dérivés de sulfonylamides destines au traitement d'une croissance cellulaire anormale
TNSN06370A1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
MA30075B1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
MA31466B1 (fr) Derives de benzimidazole
TNSN06358A1 (fr) Methyl-aryl-ou-heteroaryl-amides substitues
MA30526B1 (fr) Inhibiteurs de prolyle hydroxylase
MA31655B1 (fr) Pyrimidines cyclopenta [d] hydroxylés et méthoxylés utilisés en tant qu'inhibiteurs de la protéine kinase akt.
TNSN05249A1 (fr) Benzopyrannes utiles pour le traitement d'etats inflammatoires
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA31419B1 (fr) Derives de pyridine
TNSN08306A1 (fr) Imidazoles substitutes et leur utilisation comme pesticides
TNSN08196A1 (fr) Derives de pyrazine
MA30428B1 (fr) Derives de dihydropyrazolopyrimidinones
MA27561A1 (fr) Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
ATE368031T1 (de) Neue gamma secretase inhibitoren
TNSN06359A1 (fr) Aryl-ou heteroaryl-amides substitues en position ortho
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MY135477A (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
TNSN06347A1 (fr) Derives de morpholine
CL2004000366A1 (es) USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
MA30351B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation